Pharmaceutical Executive January 1, 2025
GLP-1s continue to dominate the market, but can pharma keep up with the demand?
The Weight-Loss Gold Rush: Legal and Regulatory Implications
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Beyond GLP-1s: Q&A with Sandeep Makkar
The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care when treating obesity.
...Today's Sponsors
Today's Sponsor